Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA

Future Microbiology

Volumn 10, Issue 6, 2015, Pages 1049-1062

  Amin, Alpesh N ^a   Deruelle, Dennis ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IPC Healthcare   (United States)

Author keywords

antibiotic; burden of disease; drug development; Gram negative pathogen; healthcare associated infection

Indexed keywords

ACORAFLOXACIN; ANTIBIOTIC AGENT; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; CEFTAROLINE; CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; ERAVACYCLINE; METRONIDAZOLE; NEMONOXACIN; OMADACYCLINE; PLAZOMICIN; RELEBACTAM; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC THERAPY; CATHETER INFECTION; CLINICAL PRACTICE; DISEASE SURVEILLANCE; DRUG LEGISLATION; DRUG RESEARCH; ENTEROBACTER; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SERVICE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; UNITED STATES; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; CROSS INFECTION; DRUG DEVELOPMENT; GRAM-NEGATIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; PROCEDURES; TRENDS;

NEGIBACTERIA;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG DISCOVERY; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEALTH POLICY; HUMANS; INFECTION CONTROL; UNITED STATES;

EID: 84930989480     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.33     Document Type: Review

References (109)

1. Cardoso T, Almeida M, Friedman ND et al. Classification of healthcare-associated infection: a systematic review 10 years after the first proposal. BMC Med. 12, 40 (2014).
2. Klevens RM, Edwards JR, Richards CL Jr et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 122(2), 160-166 (2007).
3. Sievert DM, Ricks P, Edwards JR et al. National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities. Antimicrobial-resistant pathogens associated with healthcareassociated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34(1), 1-14 (2013).
4. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197(8), 1079-1081 (2008).
5. Magill SS, Edwards JR, Bamberg W et al. Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health careassociated infections. N. Engl. J. Med. 370(13), 1198-1208 (2014).
6. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1), 1-12 (2009).
7. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49(1), 1-45 (2009).
8. O'Grady NP, Alexander M, Burns LA et al. Guidelines for the prevention of intravascular catheter-related infections. Clin. Infect. Dis. 52(9), e162-e193 (2011).
9. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171(4), 388-416 (2005).
10. Nicolle LE. AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults. Can. J. Infect. Dis. Med. Microbiol. 16(6), 349-360 (2005).
11. Lane DR, Takhar SS. Diagnosis and management of urinary tract infection and pyelonephritis. Emerg. Med. Clin. North. Am. 29(3), 539-552 (2011).
12. Mazzulli T. Diagnosis and management of simple and complicated urinary tract infections (UTIs). Can. J. Urol. 19(Suppl. 1), 42-48 (2012).
13. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 50(2), 133-164 (2010).
14. Tokars JI, Richards C, Andrus M et al. The changing face of surveillance for health care-associated infections. Clin. Infect. Dis. 39(9), 1347-1352 (2004).
15. Centers for Disease Control and Prevention. Emerging infections programs. www.cdc.gov/ncezid/dpei/eip/
16. Centers for Disease Control and Prevention. CDC's healthcare-associated infection progress report: questions and answers. www.cdc.gov/hai/surveillance/QA
17. US Department of Health & Human Services. Operating divisions. www.hhs.gov/about/foa/opdivs/index.html
18. March A. Stories of success: using CUSP to improve safety. www.ahrq.gov/professionals/quality-patient
19. Pronovost P, Needham D, Berenholtz S et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N. Engl. J. Med. 355(26), 2725-2732 (2006).
20. Goeschel CA, Pronovost PJ. Harnessing the potential of health care collaboratives: lessons from the Keystone ICU project. In: Advances in Patient Safety: New Directions and Alternative Approaches (Volume 2: Culture and Redesign). Henriksen K, Battles JB, Keyes MA, Grady ML (Eds). Agency for Healthcare Research and Quality, MD, USA (2008).
21. ON the CUSP: Stop HAI. www.onthecuspstophai.org
22. American Urological Association. Antimicrobial prophylaxis. www.auanet.org/education/guidelines
23. Jarlier V, Trystram D, Brun-Buisson C et al. Curbing methicillin-resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program. Arch. Intern. Med. 170(6), 552-559 (2010).
24. Climo MW, Yokoe DS, Warren DK et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N. Engl. J. Med. 368(6), 533-542 (2013).
25. Milstone AM, Elward A, Song X et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicenter, cluster-randomised, crossover trial. Lancet 381(9827), 1099-1106 (2013).
26. Huang SS, Septimus E, Kleinman K et al. Targeted versus universal decolonization to prevent ICU infection. N. Engl. J. Med. 368(24), 2255-2265 (2013).
27. Anderson DJ, Gergen MF, Smathers E et al. Decontamination of targeted pathogens from patient rooms using an automated ultraviolet-C-emitting device. Infect. Control Hosp. Epidemiol. 34(5), 466-471 (2013).
28. Centers for Disease Control and Prevention. Duke University Prevention Epicenter. www.cdc.gov/hai/epiCenters
29. Centers for Disease Control and Prevention. Healthcare-associated infections (HAIs). www.cdc.gov/HAI/prevent
30. Association of State and Territorial Health Officials (ASTHO) and Centers for Disease Control and Prevention (CDC). Eliminating healthcare-associated infections: state policy options. Association of State and Territorial Health Officials (ASTHO), VA, USA (2011). www.cdc.gov/hai/pdfs/toolkits
31. Office of Disease Prevention and Health Promotion. Healthcare-associated infections targets. www.health.gov/hai/pdfs/HAI-Targets.pdf
32. Office of Disease Prevention and Health Promotion. National action plan to prevent health care-associated infections. www.health.gov/hai/pdfs
33. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44(2), 159-177 (2007).
34. Nowak MA, Nelson RE, Breidenbach JL, Thompson PA, Carson PJ. Clinical and economic outcomes of a prospective antimicrobial stewardship program. Am. J. Health Syst. Pharm. 69(17), 1500-1508 (2012).
35. Prasad N, Warren N, Kula A et al. Impact of antibiotic stewardship program interventions on multi-drug resistant organism resistance rates and hospital costs. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 5-9 September 2014.
36. Pasquale TR, Trienski TL, Olexia DE et al. Impact of an antimicrobial stewardship program on patients with acute bacterial skin and skin structure infections. Am. J. Health Syst. Pharm. 71(13), 1136-1139 (2014).
37. Septimus E, Weinstein RA, Perl TM, Goldman DA, Yokoe DS. Approaches for preventing healthcare-associated infections: go long or go wide? Infect. Control Hosp. Epidemiol. 35(7), 797-801 (2014).
38. Kuper KM, Septimus EJ. Health-careassociated infections: the legislative perspective and the pharmacist's role. Am. J. Health Syst. Pharm. 66(5), 488-494 (2009).
39. The Hospitalist. Medicare penalties make hospital-aquired-infection solutions a priority. www.the-hospitalist.org/details
40. Centers for Medicare & Medicaid Services. CMS final rule to improve quality of care during hospital inpatient stays. www.cms.gov/newsroom
41. Centers for Medicare & Medicard Services. Hospital inpatient quality reporting program. www.cms.gov/Medicare/Quality-Initiatives
42. Centers for Medicare & Medicard Services. Hospital value-based purchasing. www.cms.gov/Medicare/Quality
43. Centers for Medicare & Medicard Services. Readmissions reduction program. www.cms.gov/Medicare/Medicare
44. Boston Scientific. FY2015 final hospital inpatient rule summary. www.bostonscientific.com/content/dam
45. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38(9), 1279-1286 (2004).
46. CenterWatch. FDA approved drugs for infections and infectious diseases. www.centerwatch.com/drug-information
47. Teflaro® (ceftaroline fosamil) for injection. www.teflaro.com
48. Basilea Pharmaceutica. Ceftobiprole. www.basilea.com/Development/Ceftobiprole
49. BioSpace. Janssen-Cilag AG announces CHMP delays European Commission decision process to approve ZEVTERATM. www.biospace.com/News
50. Perez F, Salata RA, Bonomo RA. Current and novel antibiotics against resistant Gram-positive bacteria. Infect. Drug Resist. 1, 27-44 (2008).
51. Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin. Infect. Dis. 56(10), 1445-1450 (2013).
52. Williams KJ, Bax RP. Challenges in developing new antibacterial drugs. Curr. Opin. Investig. Drugs. 10(2), 157-163 (2009).
53. Livermore DM. British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: regenerating antibacterial drug discovery and development. Discovery research: the scientific challenge of finding new antibiotics. J. Antimicrob. Chemother. 66(9), 1941-1944 (2011).
54. Slama TG. Gram-negative antibiotic resistance: there is a price to pay. Crit. Care 12(Suppl. 4), S4 (2008).
55. Sharma P, Towse A. New drugs to tackle antimicrobial resistance: analysis of EU policy options. www.ohe.org/publications/article
56. Food and Drug Administration. News release: new FDA task force will support innovation in antibacterial drug development. www.fda.gov/NewsEvents/Newsroom
57. Food and Drug Administration. Guidance for industry: applications covered by Section 505(b)(2). www.fda.gov/downloads/Drugs/Guidances
58. Infectious Diseases Society of America. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50(8), 1081-1083 (2010).
59. Boucher HW, Talbot GH, Benjamin DK Jr et al. Infectious Diseases Society of America. 10 x '20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56(12), 1685-1694 (2013).
60. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J. Antibiot. (Tokyo) 66(10), 571-591 (2013).
61. ClinicalTrials.gov NCT02096328. http://clinicaltrials.gov/show/NCT02096328
62. Daiichi-Sankyo. Major R&D pipeline. www.daiichisankyo.com/rd/pipeline/pdf
63. Page MG, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob. Agents Chemother. 54(6), 2291-2302 (2010).
64. Mushtaq S, Woodford N, Hope R, Adkin R, Livermore DM. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenemresistant Enterobacteriaceae and nonfermenters. J. Antimicrob. Chemother. 68(7), 1601-1608 (2013).
65. Basilea Pharmaceutica. BAL30072. www.basilea.com/Development/BAL30072
66. Cellceutix. http://cellceutix.com
67. Higuchi S, Onodera Y, Chiba M, Hoshino K, Gotoh N. Potent in vitro antibacterial activity of DS-8587, a novel broad-spectrum quinolone, against Acinetobacter baumannii. Antimicrob. Agents Chemother. 57(4), 1978-1981 (2013).
68. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob. Agents Chemother. 57(11), 5548-5558 (2013).
69. Solomkin JS, Ramesh MK, Cesnauskas G et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob. Agents Chemother. 58(4), 1847-1854 (2014).
70. Business Wire. FDA grants QIDP designation to eravacycline, tetraphase's lead antibiotic production candidate. www.businesswire.com/news
71. ClinicalTrials.gov NCT01844856. http://clinicaltrials.gov/show/NCT01844856
72. ClinicalTrials.gov NCT01978938. http://clinicaltrials.gov/ct2/show/NCT01978938
73. Landman D, Babu E, Shah N et al. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J. Antimicrob. Chemother. 65(10), 2123-2127 (2010).
74. Landman D, Kelly P, Bäcker M et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J. Antimicrob. Chemother. 66(2), 332-334 (2011).
75. Galani I, Souli M, Daikos GL et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J. Chemother. 24(4), 191-194 (2012).
76. Cass RT, Brooks CD, Havrilla NA et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob. Agents Chemother. 55(12), 5874-5880 (2011).
77. ClinicalTrials.gov NCT01096849. http://clinicaltrials.gov/ct2/show/NCT01096849
78. Achaogen. Plazomicin. www.achaogen.com/plazomicin
79. ClinicalTrials.gov NCT01970371. www.clinicaltrials.gov/ct2/show/NCT01970371
80. Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we? Ann. Clin. Microbiol. Antimicrob. 12, 22 (2013).
81. Biedenbach DJ, Turner LL, Jones RN, Farrell DJ. Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains. Diagn. Microbiol. Infect. Dis. 74(2), 204-206 (2012).
82. Furiex® Pharmaceuticals. JNJ-Q2. www.furiex.com/pipeline
83. Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 51(3), 826-830 (2007).
84. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob. Agents Chemother. 55(5), 2390-2394 (2011).
85. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozanetazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob. Agents Chemother. 57(12), 6305-6310 (2013).
86. Lucasti C, Hershberger E, Miller B et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob. Agents Chemother. 58(9), 5350-5357 (2014).
87. Cubist Pharmaceuticals. FDA grants QIDP designation to two cubist Phase 3 antibiotic candidates. http://investors.cubist.com/Mobile
88. Cubist Pharmaceuticals. Ceftolozanetazobactam. www.cubist.com
89. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 56(7), 3753-3757 (2012).
90. Business Wire. Merck's investigational beta-lactamase inhibitor relebactam (MK-7655) granted qualified infectious disease product (QIDP) and fast track designations by FDA. www.businesswire.com/news
91. Stachyra T, Levasseur P, Péchereau MC et al. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64(2), 326-329 (2009).
92. Zhanel GG, Lawson CD, Adam H et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73(2), 159-177 (2013).
93. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55(1), 390-394 (2011).
94. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J. Antimicrob. Chemother. 65(11), 2376-2381 (2010).
95. Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN. Activity of ceftarolineavibactam tested against gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob. Agents Chemother. 56(9), 4779-4785 (2012).
96. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J. Antimicrob. Chemother. 68(5), 1183-1192 (2013).
97. Vazquez JA, González Patzán LD, Stricklin D et al. Efficacy and safety of ceftazidimeavibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr. Med. Res. Opin. 28(12), 1921-1931 (2012).
98. Forest Laboratories, Inc. Ceftazidime/avibactam combination receives qualified infectious disease product (QIDP) designation from FDA. http://investor.frx.com/press-release
99. ClinicalTrials.gov NCT01499290. www.clinicaltrials.gov/ct2/show/NCT01499290
100. ClinicalTrials.gov NCT01599806. www.clinicaltrials.gov/ct2/show/NCT01599806
101. ClinicalTrials.gov NCT01808092. https://clinicaltrials.gov/ct2/show/NCT01808092
102. ClinicalTrials.gov search. https://clinicaltrials.gov/ct2/results
103. Peacock S. Health care: bring microbial sequencing to hospitals. Nature 509(7502), 557-559 (2014).
104. Zumla A, Al-Tawfiq JA, Enne VI, Kidd M, Drosten C, Breuer J et al. Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections: needs, advances, and future prospects. Lancet Infect. Dis. 14(11), 1123-1135 (2014).
105. Dandekar T, Dandekar G. Pharmacogenomic strategies against microbial resistance: from bright to bleak to innovative. Pharmacogenomics 11(9), 1193-1196 (2010).
106. Baietto L, Corcione S, Pacini G, Di Perri G, D'Avolio A, De Rosa FG. A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr. Drug Metab. 15(6), 581-598 (2014).
107. Carlet J. The gut is the epicentre of antibiotic resistance. Antimicrob. Resist. Infect. Control 1(1), 39 (2012).
108. O'Connor N, Cahill O, Daniels S, Galvin S, Humphreys H. Cold atmospheric pressure plasma and decontamination. Can it contribute to preventing hospital-acquired infections? J. Hosp. Infect. 88(2), 59-65 (2014).
109. Denham ME, Kasali A, Steinberg JP, Cowan DZ, Zimring C, Jacob JT. The role of water in the transmission of healthcare-associated infections: opportunities for intervention through the environment. HERD 7(Suppl.), 99-126 (2013).